Literature DB >> 27039091

The challenges of outcome research.

Lene Juel Kjeldsen1, Trine Rune Høgh Nielsen2, Charlotte Olesen3.   

Abstract

Cognitive pharmacy trials seek to identify interventions that benefit patients. The potential benefits of an intervention are primarily evaluated by outcome measures. The question then is: What is the optimal outcome measure? Unfortunately, the question remains unsolved. Several factors must be taken into consideration when conducting outcome research-particularly within cognitive pharmacy trials. The interventions are often complex and non-specific, and seek to improve symptom control, optimise the use of medications and reduce medication-related risks. "Hard" endpoints, such as mortality and hospital admissions, may not be the optimal outcome measures, since cognitive pharmacy interventions are unlikely to result in changes in these measures. Instead, adverse drug events or "soft" endpoints, such as quality of life, drug-related problems and patient satisfaction may be appropriate choices of outcome measures. Finally, it is not only outcome measures that may pose a challenge when conducting outcome research; other essential components include study design, type of intervention, the patient population, etc.

Entities:  

Keywords:  Cognitive pharmacy intervention; Outcome; Patient satisfaction; Quality of life

Mesh:

Year:  2016        PMID: 27039091     DOI: 10.1007/s11096-016-0293-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  14 in total

1.  The impact of pharmacist interventions on health-related quality of life.

Authors:  A S Pickard; J A Johnson; K B Farris
Journal:  Ann Pharmacother       Date:  1999-11       Impact factor: 3.154

Review 2.  Interpretation of observational studies.

Authors:  P Jepsen; S P Johnsen; M W Gillman; H T Sørensen
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

3.  Introduction to surrogate markers.

Authors:  Jay N Cohn
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

4.  Outcome measures: a sensitive approach.

Authors:  Janet Krska; Philip H Rowe
Journal:  Int J Pharm Pract       Date:  2010-04

5.  Biomarkers and surrogate endpoints.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

Review 7.  Randomised controlled trials (RCTs) to evaluate complex healthcare interventions--a case study.

Authors:  Ian Chi Kei Wong
Journal:  Pharm World Sci       Date:  2004-10

Review 8.  Pharmacists and prescribing rights: review of international developments.

Authors:  Lynne Emmerton; Jennifer Marriott; Tracey Bessell; Lisa Nissen; Laura Dean
Journal:  J Pharm Pharm Sci       Date:  2005-08-04       Impact factor: 2.327

9.  The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus.

Authors:  Aleksandra Wieczorek; Przemyslaw Rys; Iwona Skrzekowska-Baran; Maciej Malecki
Journal:  Rev Diabet Stud       Date:  2008-11-10

10.  Developing and evaluating complex interventions: the new Medical Research Council guidance.

Authors:  Peter Craig; Paul Dieppe; Sally Macintyre; Susan Michie; Irwin Nazareth; Mark Petticrew
Journal:  BMJ       Date:  2008-09-29
View more
  3 in total

Review 1.  Pharmaceutical care and health related quality of life outcomes over the past 25 years: Have we measured dimensions that really matter?

Authors:  Mohammed A Mohammed; Rebekah J Moles; Timothy F Chen
Journal:  Int J Clin Pharm       Date:  2018-01-10

2.  A Stepwise Pharmacist-Led Medication Review Service in Interdisciplinary Teams in Rural Nursing Homes.

Authors:  Kjell H Halvorsen; Torunn Stadeløkken; Beate H Garcia
Journal:  Pharmacy (Basel)       Date:  2019-11-05

3.  Clinical Outcomes Used in Clinical Pharmacy Intervention Studies in Secondary Care.

Authors:  Lene Juel Kjeldsen; Charlotte Olesen; Merete Kjær Hansen; Trine Rune Høgh Nielsen
Journal:  Pharmacy (Basel)       Date:  2017-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.